Drug Repositioning of the Phenylpiperazine Derivative Naftopidil in Prostate Cancer Treatment
Drug Repositioning of the Phenylpiperazine Derivative Naftopidil in Prostate Cancer Treatment
复制标题
苯基哌嗪衍生物萘哌地尔在前列腺癌治疗中的药物重新定位
DOI：
10.1007/978-981-16-9232-1_8
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Watanabe Masatoshi
中科院分区：
文献类型：
--
作者：
Ishii Kenichiro;Sugimura Yoshiki;Watanabe Masatoshi
纳夫托地尔是一种选择性α - 1肾上腺素受体拮抗剂，常用于治疗良性前列腺增生，这是一种发生在老年男性的前列腺疾病。在我们实验室进行的药物重新定位研究中，我们证明了naftopidil通过诱导癌细胞、成纤维细胞和血管内皮细胞的g1细胞周期阻滞而具有生长抑制作用。此外，naftopidil已被证明可以直接结合并抑制微管的聚合；因此，萘托地尔可能在许多类型的细胞中表现出普遍的细胞毒性。近年来的证据表明，加用萘托地尔联合化疗可能是治疗前列腺癌的一种新的临床应用。
Naftopidil, a selective α1-adrenoceptor antagonist, is commonly used for the treatment of benign prostatic hyperplasia, a prostatic disease occurring in elderly men. In drug repositioning studies conducted from our laboratory, we demonstrated that naftopidil has growth inhibitory effects by inducing G1cell cycle arrest in cancer cells, fibroblasts, and vascular endothelial cells. Moreover, naftopidil has been shown to bind directly to and inhibit the polymerization of tubulins; thus, naftopidil may exhibit general cytotoxicity in many types of cells. Recent evidence has supported that additive naftopidil treatment in combination with chemotherapy could be a new clinical application for the treatment of prostate cancer.